Prostate Hyperplasia, Urinary Bladder Neoplasms
Conditions
Brief summary
Patients followed in the Foch Hospital Urology Department (Suresnes): Patients justifying a prostatectomy. * Patients justifying prostatectomy together with the bladder (radical cystectomy for bladder cancer). * Patients with benign prostate hyperplasia who justified a prostatectomy. Compare serum sexual steroid concentrations and intra-tissue on healthy prostates and prostate adenoma, assess concentrations intra-tissue sex steroids on cancer metastasis prostate specific blood sample under study (30mL) will be performed preoperatively in Patients followed in Foch Hospital Urology Department (Suresnes), and a Removal of a fragment of prostate tissue or metastasis will be analyze. Aim is to compare serum concentrations of sexual steroids and intra-tissue on healthy prostates and prostate adenomas compared to concentrations measured in patients operated for prostate cancer.
Detailed description
Steroids concentration will be determined using Gas chromatography-mass spectrometry. The analyzed steroids are : FSH :Mul/ml LH: mUI/ml SHBG: µg/ml BT: ng/ml TT: ng/ml DHT: ng/ml DHEA: ng/ml D5: ng/ml D4: ng/ml E1: pg/ml E2 : pg/ml DHEA-S : µg/dl
Interventions
BIOLOGICALsteroids concentrations determination
Sponsors
Hopital Foch
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men aged over 18 years * Surgical indication justifying protatique prostatectomy, or complete prostatocystectomie, or removal of a metastasis of prostate cancer. * Patients affiliated to a social security scheme or benefiting from such a regime. * Patients who have given their consent to participate in writing
Exclusion criteria
* Patient received local therapy or hormonal treatment (LHRH analogue, therapy blocking androgen receptors) before surgery. * Treatment reductase inhibitors 5ARI ongoing or stopped for less than 3 months before the intervention. * Patient included in another clinical trial inconsistent with the conduct of this research. * Patient receiving treatment that could interfere with hormone levels (Prednisone, Ketoconazole, Abiraterone, Finasteride, Dutasteride).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum concentrations of sexual steroids and intra-tissue on healthy prostates | 30 minutes | A bio-informatical analysis will be performed to compare steroids concentrations profiles in both arms. |
Countries
France
Outcome results
None listed